Orthocell (ASX:OCC) was granted a medical device license by Health Canada to start sales of its nerve repair collagen wrap Remplir in the country, according to a Wednesday Australian bourse filing.
The firm noted that the approval was granted earlier than expected after it lodged an application in February.
The company is currently in talks to appoint non-exclusive local specialist distribution partners in Canada to drive market penetration, and the first sales are expected in the second half, the filing said.
Orthocell's shares surged past 13% in recent trading on Wednesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。